Slide 1: Virtual KOL Event: MB-107 Soft Tissue Sarcoma Lung Mets
o 8 oon MOLECULIN Virtual KOL Event MB-107: Soft Tissue Sarcoma (STS) Lung Mets June 5, 2025
Slide 2: Disclaimer
Disclaimer \ All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position four business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe
Slide 3: Opening and Introductions
._ Opening and Introductions STS Lung Mets: Overview and Unmet Need Annamycin: Relevance in STS Lung Mets MB-107 Trial Overview and Topline Data
Slide 4: Moleculin speakers: Walter Klemp and John Paul Waymack
oceMOLECULIN op Walter V. Klemp John Paul Waymack, MD CEO and Chairman Senior Chief Medical Officer
Slide 5: Prof. Bernd Kasper
Prof. Bernd Kasper Sarcoma Unit of the Mannheim Cancer Center (MCC) at the Mannheim University Medical Center, University of Heidelberg * Head of the study center of the German interdisciplinary Sarcoma Group (GISG) and is active in national and international study groups (AIO, EORTC) + Principal In
Slide 6: Mohamad Cherry, MD
Mohamad Cherry, MD Medical Director of Hematology, Atlantic Health System + Principal Investigator of multiple clinical trials, performing groundbreaking research in niche areas that include epigenetics in sarcomas and relapsed refractory Blood Cancers * Clinical Associate Professor of Hematology/On
Slide 7: Sant P. Chawla, MD
Sant P. Chawla, MD Director of Sarcoma Oncology Center in Santa Monica, CA * World-renowned leader in the field of sarcoma oncology, dedicating his career to improving the lives of patients battling bone and soft-tissue sarcomas + Unwavering commitment to research and innovation has led to groundbre
Slide 8: STS Lung Mets: Overview and Unmet Need
STS Lung Mets: Overview and Unmet Need
Slide 9: Soft Tissue Sarcoma (STS) Lung Mets
Soft Tissue Sarcoma (STS) Lung Mets Rare and aggressive cancer with a high a 7 risk of lung metastases, leading to poor survival and limited treatment options New Cases Annually Lung metastases are the most frequent ~13,000 in the US? and clinically significant site of spread: wi of metastatic 70 —
Slide 10: Current Treatment Options
Current Treatment Options 1° Line: Standard of Care (Non-surgical candidates) 2°4 Line Refractory Disease: Histology-Driven Approaches: Emerging & Investigational Approaches: Anthracycline-based chemotherapy remains the backbone of first-line treatment th oF + Typically, doxorubicin }out ifosfamide
Slide 11: Limitations of Current Treatments & Unmet Need in Advanced STS
Limitations of Current Treatments & Unmet Need in Advanced STS Limited Efficacy * Response rates with frontline doxorubicin-based chemotherapy are low (typically <25%) + Most patients progress within 6-12 months, even with combination therapy Toxicity Concerns + Cumulative cardiotoxicity limits long
Slide 12: Topic Round Table
Topic Round Table STS Lung Mets: Overview and Unmet Need rN Prof. Bernd Kasper Mohamad Cherry, MD Sant P. Chawla, MD
Slide 13: Annamycin: Relevance in STS Lung Mets
Annamycin: Relevance in STS Lung Mets ‘ John Paul Waymack, MD « » Senior Chief Medical Office 0 . oa Bmorecuun
Slide 14: Annamycin: A Next-Generation Anthracycline
Annamycin: A Next-Generation Anthracycline ome £ ~onon om 7 le em 9 sei Annamycin ee Sor ton ye Son ™ <i eH0n Y to & be Epirubicin Idarubicin Doxorubicin
Slide 15: Eliminating Cardiotoxicity
Eliminating Cardiotoxicity 100% Cardiac Event FDA Lifetime Limit Wee >8% Heart Failure 65% Cardiac Event |< Level \ y y >3000 mine Zero Cardiotoxicity in ~100 Patients Treated 850 mone = | Currently Prescribed Anthracyclines Annamycin
Slide 16: Pharmacokinetics and Tissue Distribution of Annamycin and Doxorubicin in Rats
Pharmacokinetics and Tissue Distribution of Annamycin and Doxorubicin in Rats Lungs @ LAN 5 EF-ANN Injected agent (ae Ratio of 'p 15000 & Dox ne/e ANN’S Crnae 5 ‘ Dox 430 10000: (0.74) 1 8 F-ANN 3,899 9 & 5000: (6.1 um) L-ANN 13,352 " 31 fe 3 (20.8) on 1 10 100 "1000 Time (min) ted in lung parenchym
Slide 17: MB-107 Trial: Overview and Topline Data
MB-107 Trial: Overview and Topline Data
Slide 18: MB-107 Overview
MB-107 Overview LIPOSOMAL ANNAMYCIN (L-ANNAMYCIN}!, MB-107 ~ PHASE 18/2 STUDY OF LIPOSOMAL ANNAMYCIN (L- ANNAMYCIN) IN SUBJECTS WITH PREVIOUSLY TREATED SOFT TISSUE SARCOMAS WITH PULMONARY METASTASES ‘A multi-center, open-label, single-arm study that in Phase 1B determined the Maximum Tolerable Dose
Slide 19: Key Inclusion/Exclusion Criteria
Key Inclusion/Exclusion Criteria ( -— * Inclusion: * STS diagnosis with unresectable lung mets 210mm * Progressive Disease (“PD”) after prior systemic therapy * Estimated life span >3 months * ECOG! <2 * Age 218 * Exclusion: * Left ventricular ejection fraction (“LVEF”) <50%, evidence of heart disea
Slide 20: Median OS Outperforming in STS Lung Mets
Median OS Outperforming in STS Lung Mets Meta Analysis of 10 Studies MB-107 (n=36) and 2,267 Subjects* (Annam cin) (Range of Salvage Therapies) yi Annamycin delivering better 13.5 Months performance 7" line than 13.4 Months n 8-12 Months would be expected even in 2"4 | = | all line for monotherapy 2
Slide 21: PFS and OS Improved in Dose Dependent Manner
PFS and OS Improved in Dose Dependent Manner Median PFS (pays) Median OS (months) 127 Responders (SD or PR) a2 19.7 19.9 after 2 cycles showed improvement in OS 13.5 and PFS 63 B 210-390 me/m2, $330 210-390 me/m2, $330 Median 6 prior lines ci Median 6 prior lines enol $330 mg/m2 and $2 prior lines o
Slide 22: Topline Conclusions
Topline Conclusions — * Clinical Benefit Rate (“CBR”) was 59.4% (n=32), comprised of 18 subjects with stable disease and 1 subject with a partial response (no subjects achieved Complete Response or CR) * Dose and regimen optimized subjects demonstrated Progression Free Survival (“PFS”) of ~4 months
Slide 23: Topic Round Table
Topic Round Table MB-107 Trial: Overview and Topline Data rN Prof. Bernd Kasper Mohamad Cherry, MD Sant P. Chawla, MD
Slide 24: pmotscuum
pmotscuum We: